774 related articles for article (PubMed ID: 25979614)
1. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
2. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
4. Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes.
Faucett AM; Metz TD; DeWitt PE; Gibbs RS
Am J Obstet Gynecol; 2016 Feb; 214(2):287.e1-287.e5. PubMed ID: 26435047
[TBL] [Abstract][Full Text] [Related]
5. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
6. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
7. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
[TBL] [Abstract][Full Text] [Related]
8. Nifedipine versus placebo in the treatment of preterm prelabor rupture of membranes: a randomized controlled trial: Assessment of perinatal outcome by use of tocolysis in early labor-APOSTEL IV trial.
Nijman TA; van Vliet EO; Naaktgeboren CA; Oude Rengerink K; de Lange TS; Bax CJ; Bloemenkamp KW; van Eyck J; Kok M; Scheepers HC; Woiski M; Franx A; Mol BW; Oudijk MA
Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():79-84. PubMed ID: 27567363
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Mercer BM; Miodovnik M; Thurnau GR; Goldenberg RL; Das AF; Ramsey RD; Rabello YA; Meis PJ; Moawad AH; Iams JD; Van Dorsten JP; Paul RH; Bottoms SF; Merenstein G; Thom EA; Roberts JM; McNellis D
JAMA; 1997 Sep; 278(12):989-95. PubMed ID: 9307346
[TBL] [Abstract][Full Text] [Related]
10. Intentional early delivery versus expectant management for preterm premature rupture of membranes at 28-32 weeks' gestation: A multicentre randomized controlled trial (MICADO STUDY).
Pasquier JC; Claris O; Rabilloud M; Ecochard R; Picaud JC; Moret S; Buch D; Mellier G
Eur J Obstet Gynecol Reprod Biol; 2019 Feb; 233():30-37. PubMed ID: 30553135
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective study of neonatal outcomes at less than 32 weeks associated with indications for maternal admission and delivery.
Garite TJ; Combs CA; Maurel K; Das A; Huls K; Porreco R; Reisner D; Lu G; Bush M; Morris B; Bleich A;
Am J Obstet Gynecol; 2017 Jul; 217(1):72.e1-72.e9. PubMed ID: 28267444
[TBL] [Abstract][Full Text] [Related]
12. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Meis PJ; Klebanoff M; Thom E; Dombrowski MP; Sibai B; Moawad AH; Spong CY; Hauth JC; Miodovnik M; Varner MW; Leveno KJ; Caritis SN; Iams JD; Wapner RJ; Conway D; O'Sullivan MJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
N Engl J Med; 2003 Jun; 348(24):2379-85. PubMed ID: 12802023
[TBL] [Abstract][Full Text] [Related]
13. Preventing Preterm Birth with Progesterone in Women with a Short Cervical Length from a Low-Risk Population: A Multicenter Double-Blind Placebo-Controlled Randomized Trial.
van Os MA; van der Ven AJ; Kleinrouweler CE; Schuit E; Kazemier BM; Verhoeven CJ; de Miranda E; van Wassenaer-Leemhuis AG; Sikkema JM; Woiski MD; Bossuyt PM; Pajkrt E; de Groot CJ; Mol BW; Haak MC
Am J Perinatol; 2015 Aug; 32(10):993-1000. PubMed ID: 25738790
[TBL] [Abstract][Full Text] [Related]
14. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial.
Porreco R; Garite TJ; Combs CA; Maurel K; Huls CK; Baker S; Fortner KB; Longo SA; Nageotte M; Lewis D; Tran L;
Am J Obstet Gynecol MFM; 2023 May; 5(5):100896. PubMed ID: 36796641
[TBL] [Abstract][Full Text] [Related]
15. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and 2-year outcomes within a national population-based study (EPIPAGE-2).
Lorthe E; Torchin H; Delorme P; Ancel PY; Marchand-Martin L; Foix-L'Hélias L; Benhammou V; Gire C; d'Ercole C; Winer N; Sentilhes L; Subtil D; Goffinet F; Kayem G
Am J Obstet Gynecol; 2018 Sep; 219(3):298.e1-298.e14. PubMed ID: 29852153
[TBL] [Abstract][Full Text] [Related]
16. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes.
Lee MJ; Davies J; Guinn D; Sullivan L; Atkinson MW; McGregor S; Parilla BV; Hanlon-Lundberg K; Simpson L; Stone J; Wing D; Ogasawara K; Muraskas J
Obstet Gynecol; 2004 Feb; 103(2):274-81. PubMed ID: 14754695
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
18. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
19. Progesterone does not prevent preterm births in women with twins.
Briery CM; Veillon EW; Klauser CK; Martin RW; Chauhan SP; Magann EF; Morrison JC
South Med J; 2009 Sep; 102(9):900-4. PubMed ID: 19668021
[TBL] [Abstract][Full Text] [Related]
20. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
